AU2011274496B2 - Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof - Google Patents

Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof Download PDF

Info

Publication number
AU2011274496B2
AU2011274496B2 AU2011274496A AU2011274496A AU2011274496B2 AU 2011274496 B2 AU2011274496 B2 AU 2011274496B2 AU 2011274496 A AU2011274496 A AU 2011274496A AU 2011274496 A AU2011274496 A AU 2011274496A AU 2011274496 B2 AU2011274496 B2 AU 2011274496B2
Authority
AU
Australia
Prior art keywords
deuterium
compound
laquinimod
carboxamide
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011274496A
Other languages
English (en)
Other versions
AU2011274496A1 (en
Inventor
Avital Laxer
Victor Piryatinsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45439026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011274496(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2011274496A1 publication Critical patent/AU2011274496A1/en
Application granted granted Critical
Publication of AU2011274496B2 publication Critical patent/AU2011274496B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
AU2011274496A 2010-07-09 2011-07-08 Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof Ceased AU2011274496B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39929710P 2010-07-09 2010-07-09
US61/399,297 2010-07-09
PCT/US2011/043383 WO2012006538A1 (en) 2010-07-09 2011-07-08 Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

Publications (2)

Publication Number Publication Date
AU2011274496A1 AU2011274496A1 (en) 2013-02-28
AU2011274496B2 true AU2011274496B2 (en) 2016-03-10

Family

ID=45439026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011274496A Ceased AU2011274496B2 (en) 2010-07-09 2011-07-08 Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

Country Status (20)

Country Link
US (3) US8580819B2 (enExample)
EP (2) EP3213636A1 (enExample)
JP (2) JP2013535437A (enExample)
KR (1) KR20130092558A (enExample)
CN (2) CN104610144A (enExample)
AR (1) AR082150A1 (enExample)
AU (1) AU2011274496B2 (enExample)
BR (1) BR112013000599A2 (enExample)
CA (1) CA2804986A1 (enExample)
CL (1) CL2013000063A1 (enExample)
EA (1) EA025377B1 (enExample)
IL (1) IL251600A0 (enExample)
MX (1) MX2013000333A (enExample)
NZ (1) NZ606587A (enExample)
PE (1) PE20130396A1 (enExample)
PH (1) PH12013500065A1 (enExample)
SG (2) SG186948A1 (enExample)
UY (1) UY33504A (enExample)
WO (1) WO2012006538A1 (enExample)
ZA (1) ZA201300956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617477A2 (pt) * 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
KR20130006640A (ko) * 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EA201290860A1 (ru) * 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
US20110217295A1 (en) * 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) * 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
CN103145562B (zh) * 2013-03-18 2015-06-17 黄河三角洲京博化工研究院有限公司 一种n-乙基苯胺的制备方法
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
EP3347006B1 (en) 2015-03-20 2022-07-27 GABA Therapeutics Inc. Deuterated analogs of etifoxine, their derivatives and uses therof
US11861914B2 (en) * 2019-08-28 2024-01-02 Nissan Motor Co., Ltd. Object recognition method and object recognition device
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
WO2005074899A2 (en) * 2004-02-06 2005-08-18 Active Biotech Ab New compositions containing quinoline compounds
US20070088050A1 (en) * 2005-10-19 2007-04-19 Anton Frenkel Crystals of laquinimod sodium, and process for the manufacture thereof
US20100055072A1 (en) * 2008-09-03 2010-03-04 Auspex Pharmaceuticals, Inc. 2-oxo-1,2-dihydro-quinoline modulators of immune function

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
EE200100660A (et) 1999-06-07 2003-04-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Ravimvorm happe suhtes labiilsete toimeainete jaoks, toimeaine üksus, selle valmistamismeetod ja mikrokerake
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
NZ597378A (en) 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
BR112012002124A2 (pt) 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
KR20130006640A (ko) 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
US20110217295A1 (en) 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
JP5934202B2 (ja) 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
PE20140872A1 (es) 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
WO2005074899A2 (en) * 2004-02-06 2005-08-18 Active Biotech Ab New compositions containing quinoline compounds
US20070088050A1 (en) * 2005-10-19 2007-04-19 Anton Frenkel Crystals of laquinimod sodium, and process for the manufacture thereof
US20100055072A1 (en) * 2008-09-03 2010-03-04 Auspex Pharmaceuticals, Inc. 2-oxo-1,2-dihydro-quinoline modulators of immune function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TUVESSON, H. ET AL., "CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR", Drug Metabolism and Disposition, 2005, 33 (6), p866-872 *

Also Published As

Publication number Publication date
UY33504A (es) 2012-02-29
US20140051723A1 (en) 2014-02-20
AU2011274496A1 (en) 2013-02-28
BR112013000599A2 (pt) 2016-07-05
CN102984939A (zh) 2013-03-20
PH12013500065A1 (en) 2017-10-25
US20140343096A1 (en) 2014-11-20
EP2597954A4 (en) 2014-01-01
NZ606587A (en) 2015-03-27
SG10201505236YA (en) 2015-08-28
SG186948A1 (en) 2013-02-28
EP2597954A1 (en) 2013-06-05
EP3213636A1 (en) 2017-09-06
US20120010238A1 (en) 2012-01-12
US9102620B2 (en) 2015-08-11
CN104610144A (zh) 2015-05-13
EA025377B1 (ru) 2016-12-30
KR20130092558A (ko) 2013-08-20
CA2804986A1 (en) 2012-01-12
JP2013535437A (ja) 2013-09-12
WO2012006538A8 (en) 2013-05-23
EA201390081A1 (ru) 2013-07-30
MX2013000333A (es) 2013-02-26
JP2017014238A (ja) 2017-01-19
AR082150A1 (es) 2012-11-14
WO2012006538A1 (en) 2012-01-12
PE20130396A1 (es) 2013-04-19
CL2013000063A1 (es) 2013-05-03
IL251600A0 (en) 2017-06-29
US8580819B2 (en) 2013-11-12
ZA201300956B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
US9102620B2 (en) Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
AU2018204671B2 (en) Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
US20180140592A1 (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
US9216956B2 (en) Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2000006550A1 (en) Phenylazole compounds, process for producing the same and drugs for hyperlipemia
AU2013259779B2 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
WO2021150885A1 (en) Cannabinoid derivatives
HK1236069A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN112759549A (zh) 3-取代氨基-4-((取代吡啶基)氨基)环丁-3-烯-1,2-二酮类化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired